Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort

Selin Cooper Blenkinsopp,1 Qinggong Fu,2 Yulia Green,3 Anuradha Madan,2 Patricia Juliao,2,4 Daniel W Goldman,4 David A Roth,2 Michelle A Petri2

ABSTRACT

Objective This retrospective analysis evaluated the prognostic value of renal response status 2 years after biopsy-proven lupus nephritis (LN) for the prediction of long-term renal outcomes.

Methods Eligible patients with SLE as per American College of Rheumatology or Systemic Lupus International Collaborating Clinics criteria and biopsy-proven class III, IV, V or mixed LN were identified from the Hopkins Lupus Cohort, and categorised into binary renal response categories (modified primary efficacy renal response (mPERR) or no mPERR at 2 years post biopsy). These categories were defined by a modified version of the Belimumab International Lupus Nephritis Study (BLISS-LN) protocol using urine protein:creatinine ratio (≥0.7 g/day) and estimated glomerular filtration rate (≥60 mL/min/1.73 m² or ≤20% below the baseline value) criteria. Long-term renal survival (defined as survival without end-stage renal disease (ESRD) or death) and chronic renal insufficiency-free survival were assessed in Kaplan–Meier plots with log-rank test and covariate-adjusted Cox proportional hazards models.

Results Of the 173 eligible patients, 91.3% were female; the mean (SD) age at biopsy was 36.2 (11.8) years. At 2 years post biopsy, 114 (65.9%) patients achieved mPERR. These patients showed a lower risk of ESRD/death and chronic renal insufficiency-free survival were assessed in Kaplan–Meier plots with log-rank test and covariate-adjusted Cox proportional hazards models.

Conclusion The 2-year post-biopsy renal response status, defined per 2019-updated BLISS-LN criteria, has prognostic value for long-term renal survival and lower risk of chronic renal insufficiency in patients with LN.

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT?

End-stage renal disease, a condition associated with lupus nephritis (LN), is a strong predictor of poor disease prognosis; as such, the identification of early-stage predictors of long-term renal outcomes would be of value in clinical practice and LN trials.

WHAT DOES THIS STUDY ADD?

This retrospective analysis of the Hopkins Lupus Cohort evaluated the prognostic value of a defined renal response status assessed at 2 years post-LN diagnosis for the prediction of long-term renal outcomes.

Enduring renal response status at 2 years is associated with a lower risk of end-stage renal disease (ESRD) and death; as such, the identification of early-stage predictors of long-term renal survival and chronic renal insufficiency-free survival in patients with LN.

INTRODUÇÃO

Lupus nephritis (LN) is a common and severe manifestation of SLE that is present in 38% of patients at SLE diagnosis, and occurs in as many as 70% of patients with SLE during the course of their disease, depending on factors such as age, gender, race and ethnicity.1-3 LN accounts for substantial morbidity and mortality in patients with SLE.1,5 One study reported that patients with SLE and LN had an approximately threefold higher standardised mortality ratio than patients with SLE without LN (6.8 vs 2.4).5 End-stage renal disease (ESRD) is a condition that ≥22% to ≥26% of patients develop within 15 years after LN diagnosis and is a strong indicator of poor prognosis.7 Identifying early-stage predictors of long-term renal outcomes would allow for optimisation of LN treatment in clinical practice and a consistent and accurate evaluation of treatments in LN clinical trials.

Cooper Blenkinsopp S, et al. Lupus Science & Medicine 2022;9:e000598. doi:10.1136/lupus-2021-000598
Renal response is a frequently used treatment target in LN clinical trials. Most studies have used proteinuria level and glomerular filtration rate (GFR) in their definition of renal response; however, there is no consensus on the precise combination and threshold levels for these outcome measures. As a result, the renal response endpoints used in LN clinical trials lack uniformity and it is questionable whether they accurately predict long-term kidney survival.

A retrospective analysis of real-world data from the Hopkins Lupus Cohort by Davidson et al. examined the renal response definition used in the Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis (BLISS-LN; GSK Study BEL114054; NCT01639339) clinical trial. The Hopkins Lupus Cohort is a prospective, longitudinal, real-world study of lupus activity, organ damage and treatment of patients with SLE, which began in 1987. Within this analysis, the renal response definition was largely aligned with the BLISS-LN primary endpoint at that time (ordinal response: complete, partial, no response) but with a modification to exclude urinary sediment. This response category assessed at 2 years post biopsy was found to be a predictor of long-term renal outcomes.

Several studies have shown that a decrease in proteinuria to <0.7–0.8 g/day is a reliable predictor of long-term renal survival. In addition, estimated GFR (eGFR) <60 mL/min/1.73 m² is considered a predictor of poor renal prognosis. In contrast, urinary sediment can have confounding effects on the evaluation of renal response. Consequently, the BLISS-LN primary endpoint was modified before unblinding in 2019 to a binary ‘primary efficacy renal response’ (PERR) at 2 years post biopsy. To harmonise with growing evidence on predictors of long-term renal outcomes, PERR was defined as urine protein:creatinine ratio (uPCR) ≤0.7 g/day, eGFR of ≤20% below the baseline value or ≥60 mL/min/1.73 m², and no use of rescue therapy for treatment failure.

This study aimed to assess the prognostic value of a modified version of the BLISS-LN study PERR endpoint (mPERR) for predicting real-world, long-term renal survival, and chronic renal insufficiency-free survival of patients with LN in the Hopkins Lupus Cohort. For the mPERR endpoint, mandatory tapering of rescue therapy was removed as a requirement, and eGFR was compared with the GFR value at biopsy, due to the real-world nature of this study.

MATERIALS AND METHODS

Study design

This was a retrospective analysis nested within the prospective, longitudinal Hopkins Lupus Cohort study. Data were collected in this cohort at each outpatient visit (at least quarterly) and included SLE clinical activity indices, laboratory data and treatment (medication and dose). The Hopkins Lupus Cohort study was approved on an annual basis by the Johns Hopkins University School of Medicine Institutional Review Board (Research Project Notification: NA_00039294), and all participants gave informed consent.

Eligible patients were identified from cohort records and patients’ renal status were categorised retrospectively into binary categories (mPERR ('responders') or no mPERR ('non-responders')) at 2 years post-biopsy date, based on laboratory data available in the cohort records.

Patients were followed up from 2 years post biopsy until censoring due to an outcome event (ESRD, death or chronic renal insufficiency), loss to follow-up or the end of study (December 2013). Each visit included measurements of serum creatinine and urinary protein (uPCR, 24-hour urinary protein (g/24 h) or urine protein semi-quantitative dipstick) levels. Due to the real-world setting, the timing of renal function assessments varied. Thus, a ±3-month window for inclusion of laboratory data was defined around each interval date (i.e., baseline, 0.5, 1, 2, 3, 4 and 5 years post biopsy). Baseline was defined as the date of biopsy. An overview of the study design is shown in figure 1.

Patients

Eligible patients had SLE as per revised American College of Rheumatology (ACR) or Systemic Lupus International Collaborating Clinics (SLICC) criteria and International Society of Nephrology and the Renal Pathology Society (ISN/RPS) 2003-defined class III, IV, V or mixed lupus glomerulonephritis, proven by biopsy results. Patients were ≥18 years of age at LN diagnosis (biopsy date) and made at least one visit to the Johns Hopkins Lupus clinic in both the 3 months following biopsy and the 2 years following immunosuppressive (IS) therapy (cyclophosphamide, mycophenolate mofetil, or azathioprine) initiation.

Patient records were required to contain sufficient data within the baseline (biopsy date) and 2 years post-biopsy windows to assess their renal response status at 2 years post biopsy. ‘Sufficient’ was defined as ≥1 serum creatinine measurement, plus either (1) measurement of the uPCR, (2) 24-hour urine protein measurement or (3) urine dipstick measurement. If multiple measures were available, uPCR was given preference over a 24-hour urine protein measurement as the former was done routinely, and the 24-hour urine protein measurement was preferred over a urine protein semi-quantitative dipstick score.

The presence of ESRD, defined as having received renal replacement therapy (dialysis or transplantation), at biopsy precluded participation.

Renal response

Binary mPERR status at 2 years post biopsy (responder or non-responder) was defined as an eGFR ≤20% below the baseline value or ≥60 mL/min/1.73 m², and uPCR ≤0.7 or 24-hour urine protein ≤0.7 g/24 h if uPCR data were missing, or urine protein semi-quantitative dipstick score
Lupus nephritis ≤1 (≤30 mg/dL) if both uPCR and 24-hour urine protein data were missing (a proxy quantitative measure created based on the published literature).

Endpoints
The primary endpoints were long-term renal survival, defined as the absence of ESRD or death between 2 years post biopsy and censoring. Secondary endpoints included (1) incidence of chronic renal insufficiency defined as occurrence of kidney damage or a GFR <60 mL/min/1.73 m² recorded on ≥2 consecutive visits (≥3 months apart); (2) eGFR over time calculated from serum creatinine measurement using the Cockcroft-Gault formula; and (3) serum creatinine over time as measured during visits at 2, 3, 4 and 5 years post biopsy.

The proportion of mPERR responders who went on to achieve a modified complete renal response, defined as an eGFR >90 mL/min/1.73 m², and a uPCR of <0.5 (or 24-hour urine protein <0.5 g/24 h or urine protein semi-quantitative dipstick score ≤1 (≤30 mg/dL)), was also described at 3, 4 and 5 years post biopsy.

Analysis
Descriptive analyses were reported in terms of mean, median and SD for continuous variables, and as proportions for categorical variables.

The association between mPERR status at 2 years post biopsy and renal survival and chronic renal insufficiency-free survival post 2 years of follow-up was analysed using Kaplan–Meier plots with log-rank tests. The association between mPERR status at 2 years post biopsy and the risk of ESRD or death, or developing chronic renal insufficiency was investigated via Cox proportional hazards.
| Characteristic | mPERR response (N=114) | No mPERR response (N=59) | Total (N=173) |
|---------------|-------------------------|---------------------------|---------------|
|               | Mean (SD) | Median (min, max) | Mean (SD) | Median (min, max) | Mean (SD) | Median (min, max) |
| **Continuous variables** |            |                      |            |                      |            |                      |
| Age at biopsy date | 37.0 (11.7) | 36.0 (18.0, 66.0) | 34.8 (12.0) | 33.0 (18.0, 76.0) | 36.2 (11.8) | 35.0 (18.0, 76.0) |
| Serum creatinine (mg/dL) | 0.9 (0.4) | 0.8 (0.4, 3.0) | 1.1 (0.8) | 0.8 (0.4, 4.7) | 1.0 (0.6) | 0.8 (0.4, 4.7) |
| Urinary creatinine (mg/dL) | 132.2 (97.5) | 108.5 (27.0, 505.0) | 147.1 (147.3) | 110.0 (29.0, 655.0) | 135.7 (110.2) | 109.0 (27.0, 655.0) |
| Urinary RBC (RBC/hpf) | 9.9 (22.6) | 2.3 (0.0, 100.0) | 6.1 (14.1) | 2.5 (0.0, 100.0) | 8.6 (20.2) | 2.5 (0.0, 100.0) |
| SDI | 1.9 (2.4) | 1.0 (0.0, 10.0) | 2.6 (3.0) | 1.0 (0.0, 12.0) | 2.2 (2.6) | 1.0 (0.0, 12.0) |
| uPCR | 1.2 (1.8) | 0.5 (0.0, 9.9) | 2.6 (1.5) | 2.7 (0.5, 5.6) | 1.5 (1.8) | 0.8 (0.0, 9.9) |
| **Categorical variables** |            |                      |            |                      |            |                      |
| Female | 104 (91.2) | 54 (91.5) | 158 (91.3) |
| Race |            |                      |            |                      |            |                      |
| Black African ancestry | 55 (48.3) | 36 (61.0) | 91 (52.6) |
| Other | 59 (51.8) | 23 (39.0) | 82 (47.4) |
| LN ISN category |            |                      |            |                      |            |                      |
| III | 32 (28.1) | 12 (20.3) | 44 (25.4) |
| IV | 29 (25.4) | 21 (35.6) | 50 (28.9) |
| V | 29 (25.4) | 10 (17.0) | 39 (22.5) |
| Mixed | 24 (21.1) | 16 (27.1) | 40 (23.1) |
| IS use at baseline (3 months before or after biopsy date) |            |                      |            |                      |            |                      |
| Any IS use | 92 (80.7) | 51 (86.4) | 143 (82.7) |
| CYC | 19 (16.7) | 9 (15.3) | 28 (16.2) |
| MMF | 55 (48.2) | 32 (54.2) | 87 (50.3) |
| AZA | 8 (7.0) | 9 (15.3) | 17 (9.8) |
| IS type unknown | 10 (8.8) | 1 (1.7) | 11 (6.4) |
| None | 22 (19.3) | 8 (13.5) | 27 (15.6) |
| Missing* | 1 (0.9) | 2 (3.3) | 3 (1.7) |
| Decade of biopsy |            |                      |            |                      |            |                      |
| 1989 or earlier | 0 (0.0) | 2 (3.3) | 2 (1.2) |
| 1990–1999 | 23 (20.2) | 12 (20.3) | 35 (20.2) |
| 2000–2009 | 79 (88.3) | 43 (72.9) | 122 (70.5) |
| 2010–2013 | 12 (10.5) | 2 (8.4) | 12 (7.1) |
| Available proteinuria measures at baseline (3 months before or after biopsy date) |            |                      |            |                      |            |                      |
| uPCR | NA | NA | 69 (39.9) |
| 24-hour urine protein | NA | NA | 92 (53.2) |
| Urine protein dipstick | NA | NA | 173 (100.0) |
**Table 1** Continued

| Categorical variables                        | n (%)                          | n (%)                          | n (%)                          |
|----------------------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Proteinuria at baseline (3 months before or after biopsy date)† |                                |                                |                                |
| <0.5                                         | NA                             | NA                             | 21 (12.1)                      |
| ≥0.5                                         | NA                             | NA                             | 152 (87.9)                     |
| ≤0.7‡                                        | NA                             | NA                             | 27 (19.9)                      |
| Urine protein dipstick§ (semi-quantitative) category |                                |                                |                                |
| 0                                            | 13 (11.4)                      | 4 (6.8)                        | 17 (9.8)                       |
| 0.5                                          | 10 (8.8)                       | 2 (3.4)                        | 12 (6.9)                       |
| 1                                            | 22 (19.3)                      | 1 (1.7)                        | 23 (13.3)                      |
| 2                                            | 32 (28.1)                      | 16 (27.1)                      | 48 (27.8)                      |
| 3                                            | 33 (29.0)                      | 29 (49.2)                      | 62 (35.8)                      |
| 4                                            | 4 (3.5)                        | 7 (11.9)                       | 11 (6.4)                       |
| 5                                            | 0 (0.0)                        | 0 (0.0)                        | 0 (0.0)                        |
| Hypertension¶                               | 88 (77.2)                      | 47 (79.7)                      | 135 (78.0)                     |
| Diabetes                                     | 13 (11.4)                      | 14 (23.7)                      | 27 (15.6)                      |
| History of MI                               | 1 (0.9)                        | 3 (6.1)                        | 4 (2.3)                        |
| Any hydroxychloroquine use from baseline to 2 years post biopsy | 85 (74.6)                      | 35 (59.3)                      | 120 (69.4)                     |

*Refers to patients where IS use was missing or not captured within the time period window at baseline (in the 3 months before or after the biopsy date) within the study database.
†Proteinuria measurement data were selected using a hierarchical approach, with uPCR as the first choice, followed by 24-hour urine protein (g/24 h) and lastly, semi-quantitative urine dipstick measures were used, if others not available.
‡Based on uPCR or 24-hour urine protein measurements only, as dipstick test could not assess measures from >0.5 to <3 due to the semi-quantitative nature of the test. These data were available for 136 patients.
§Dipstick results were selected for the purposes of describing the cohort at baseline, as this particular method of measuring proteinuria was complete for all patients during the baseline window. Dipstick scores of 0-1 were equivalent to urine protein of <0.5 g/24 h; dipstick scores of 2-4 were equivalent to urine protein of ≥0.5 g/24 h.
¶Defined as systolic blood pressure ≥140 or diastolic blood pressure ≥90 mmHg on two or more occasions OR hypertension recorded as part of the SDI at any visit from day 0 to 2 years post biopsy.
ACR, American College of Rheumatology; AZA, azathioprine; CYC, cyclophosphamide; IS, immunosuppressive; ISN, International Society of Nephrology; LN, lupus nephritis; MI, myocardial infarction; MMF, mycophenolate mofetil; mPERR, modified primary efficacy renal response; NA, not available; RBC/hpf, red blood cells per high power field; SD, standard deviation; SDI, SLICC/ACR damage index; SLICC, Systemic Lupus Collaborating Clinics; uPCR, urinary protein:creatinine ratio.
renal response.

glomerular filtration rate; mPERR, modified primary efficacy

Association between mPERR status at 2 years post biopsy and renal survival during follow-up

Kaplan–Meier analysis and associated log-rank test showed that there was a statistically significant increased likelihood of renal survival among mPERR responders than non-responders (p=0.0057; figure 2A). Furthermore, in the Cox proportional hazard model, after adjusting for SLICC/ACR Damage Index (SDI) and hypertension, mPERR responders had a statistically significant lower risk of ESRD or death than non-responders (HR (95% CI): 0.33 (0.13 to 0.87); p=0.0255; table 2).

The components of mPERR categorisation (ie, GFR and proteinuria levels) were explored individually. Renal survival was significantly more likely in patients with GFR ≤20% below baseline or ≥60 mL/min/1.73 m² at 2 years post biopsy than in patients who did not meet this criterion (p=0.0015; figure 2B). Regarding proteinuria, renal survival was significantly more likely for patients with uPCR ≤0.7 (or 24-hour urine protein ≤0.7 g/24 h, or urine protein semi-quantitative dipstick score ≤1 (<30 mg/dL)) than patients who did not meet this criterion (p=0.0417; figure 2C). Over the course of 5 years of follow-up, the proportion of patients with a GFR ≥60 mL/min/1.73 m² was consistently greater, and the proportion of patients with serum creatinine ≥1.0 mg/dL was consistently lower, in mPERR responders compared with mPERR non-responders (table 3).

Association between mPERR status at 2 years post biopsy and chronic renal insufficiency during follow-up

Kaplan–Meier analysis and associated log-rank test showed that responders were significantly less affected by chronic renal insufficiency than non-responders (p<0.0001) (figure 3). In addition, the Cox proportional hazard model, after adjusting for age at biopsy and hydroxychloroquine use between baseline and 2 years post biopsy, showed that responders were at a significantly lower risk of chronic renal insufficiency than non-responders (HR (95% CI): 0.26 (0.14 to 0.47); p<0.0001; table 2).

Association of complete renal response over time with mPERR

The majority (n=94/114; 82.5%) of mPERR responders also met the criteria for complete response at 2 years post biopsy. Eighty-two (71.9%) mPERR responders met complete response status at 3 years, 63 (55.3%) at 4 years and 51 (44.7%) were in complete response at 5 years post biopsy.

Of the 20 mPERR responders who did not meet the complete response criteria at 2 years post biopsy, 7 (35%), 7 (35%) and 3 (15%) patients went on to achieve complete response at 3, 4 and 5 years, respectively. The cumulative proportion of responders who achieved complete response over 5 years post biopsy was 8 (40%).

models, using univariate models, as well as covariate-adjusted models from the previous study.12

RESULTS

Study population

Overall, 173 patients from the Hopkins Lupus Cohort met the eligibility criteria. Table 1 provides an overview of the baseline characteristics. The mean (SD) age at biopsy was 36.2 (11.8) years and 91.3% were female. Patients were distributed across LN ISN/RPS classes; most patients (82.7%) had received IS therapy in the 3 months before or 3 months after biopsy. Of the 173 patients, 114 (65.9%) were mPERR responders and 59 (34.1%) were non-responders at 2 years post biopsy. The median follow-up time of the cohort was approximately 6 years.
DISCUSSION

This study investigated the use and prognostic value of a modified version of the updated primary endpoint of BLISS-LN (PERR at 2 years post biopsy) for long-term renal survival and renal function, as applied to the Hopkins Lupus Cohort. Patient classification into binary categories of mPERR or no mPERR at 2 years post biopsy showed clinical relevance for the prediction of long-term renal outcomes. Consistent with previous results, patients who showed mPERR at 2 years post biopsy were significantly more likely to achieve long-term renal survival and maintenance of renal function than those who did not.12 When analysing the individual components of mPERR, the association between proteinuria levels and renal survival was consistent with the findings of previous studies that reported proteinuria reduction (<0.7–0.8 g/day) 1 year after LN treatment initiation to be a strong predictor of long-term renal prognosis.15 18 Although the results of these studies were primarily from Caucasian patients, similar findings were observed in more diverse cohorts of patients with LN.16 28 The outcomes predicted by the updated mPERR proteinuria component (uPCR ≤0.7, or 24-hour urine protein ≤0.7 g/24 h, or urine protein semi-quantitative dipstick score ≤1 (≤30 mg/dL)) in this current study support previous indications that lower proteinuria thresholds (<0.8 g/day at 1 year) are a strong predictor of long-term renal outcomes.15 16 18 In addition, mPERR

Table 2

| Study variable | Event (n) | Censored (n) | HR (95% CI range) | P value |
|---------------|----------|-------------|-------------------|---------|
| Association between mPERR status and ESRD* or death | mPERR at 2 years post biopsy | 18 | 155 | 0.33 (0.13 to 0.87) | 0.0255 |
| | SDI | 18 | 155 | 1.13 (0.99 to 1.29) | 0.0806 |
| | Hypertension† | 18 | 155 | 4.33 (0.57 to 32.73) | 0.1552 |
| Association between mPERR status and chronic renal insufficiency‡ | mPERR at 2 years post biopsy | 43 | 130 | 0.26 (0.14 to 0.47) | <0.0001 |
| | Age at biopsy date (baseline) | 43 | 130 | 1.04 (1.02 to 1.06) | 0.0006 |
| | Hydroxychloroquine use from baseline to 2 years post biopsy | 43 | 130 | 0.50 (0.27 to 0.93) | 0.0277 |

*Clinical assessment of ESRD regardless of dialysis or transplant.
†Between baseline and 2 years post biopsy.
‡New kidney damage OR new occurrence of GFR <60 mL/min/1.73 m² on at least two consecutive measurement occasions ≥3 months apart.
ACR, American College of Rheumatology; CI, confidence interval; ESRD, end-stage renal disease; GFR, glomerular filtration rate; HR, hazard ratio; mPERR, modified primary efficacy renal response; SDI, SLICC/ACR Damage Index; SLICC, Systemic Lupus International Collaborating Clinic.

Table 3

| GFR | 1 year | 2 years | 3 years | 4 years | 5 years |
|-----|--------|--------|--------|--------|--------|
| Responders* | 114 (67.1) | 105 (67.3) | 86 (68.3) | 71 (68.3) | 64 (70.3) |
| <60 mL/min/1.73 m² | 4 (3.5) | 7 (6.7) | 6 (7.0) | 5 (7.0) | 5 (7.8) |
| ≥60 mL/min/1.73 m² | 110 (96.5) | 98 (93.3) | 80 (93.0) | 66 (93.0) | 59 (92.2) |
| Non-responders* | 56 (32.9) | 51 (32.7) | 40 (31.7) | 33 (31.7) | 27 (29.7) |
| <60 mL/min/1.73 m² | 24 (42.9) | 20 (39.2) | 15 (37.5) | 10 (30.3) | 7 (25.9) |
| ≥60 mL/min/1.73 m² | 32 (57.1) | 31 (60.8) | 25 (62.5) | 23 (69.7) | 20 (74.1) |
| Serum creatinine | | | | | |
| Responders* | 114 (67.1) | 105 (67.3) | 86 (68.3) | 71 (68.3) | 64 (70.3) |
| <1.0 mg/dL | 88 (77.2) | 81 (77.1) | 56 (65.1) | 45 (63.4) | 41 (64.1) |
| ≥1.0 mg/dL | 26 (22.8) | 24 (22.9) | 30 (34.9) | 26 (36.6) | 23 (35.9) |
| Non-responders* | 56 (32.9) | 51 (32.7) | 40 (31.7) | 33 (31.7) | 27 (29.7) |
| <1.0 mg/dL | 22 (39.3) | 22 (43.1) | 22 (55.0) | 18 (54.6) | 14 (51.9) |
| ≥1.0 mg/dL | 34 (60.7) | 29 (56.9) | 18 (45.0) | 15 (45.5) | 13 (48.2) |

*Denominator for percentage is the total number of patients with available laboratory results for each respective year.
GFR, glomerular filtration rate; mPERR, modified primary efficacy renal response.
chronic kidney disease, and as a risk factor of poorer outcomes. In the current study, the mean GFR over the 5 years of follow-up was higher in mPERR responders than in non-responders, and mPERR responders maintained lower serum creatinine values over 5 years of follow-up than non-responders. With documentation of patient details and outcomes over a relatively long follow-up, the Hopkins Lupus Cohort is one of the most characterised lupus cohorts globally. While this rich source of real-life data from a community cohort is suitable to assess the long-term clinical relevance of renal response status at 2 years post biopsy, certain limitations of the present analysis are apparent. First, as only data from patients presenting to Johns Hopkins University (ie, from the Baltimore area) were analysed, this study population may not be representative of the wider demographic makeup of the US population and treatment practices. For example, half of the study population were of Black African ancestry, and the generalisability of the results to a wider LN population may be somewhat limited. The study population may also differ from clinical trials, which often require eligible patients to have proteinuria >1 g/24 h. In addition, as the Hopkins Lupus Cohort is centered in an outpatient clinic, some patients had baseline proteinuria and initial IS therapy during a previous in-patient admission prior to cohort entry, such that the renal measures could be after treatment onset. IS pretreatment may have also been for non-renal involvement, which may have introduced bias. Missing data regarding IS use within 3 months of baseline also limited interpretation of the results. Misclassification may have also occurred through the retrospective application of clinical trial endpoint criteria to real-world data. Fully quantitative proteinuria measures were also missing for some patients prior to the adoption of uPCR; semi-quantitative urine dipstick measures were available for 99.4% of patients. However, changes over time in the availability of proteinuria metrics within the cohort may have also introduced bias. Proteinuria measurement data were selected using a hierarchical approach, with uPCR as the first choice as it was the most commonly used, followed by 24-hour urine protein (g/24 h). For patients missing these measures, semi-quantitative urine dipstick measures were used, and proxy quantitative measures were created based on the published literature. These measures can be limited by multiple confounders (eg, urine concentration and pH) and the semi-quantitative nature of the urine dipstick. Finally, the decrease of patient numbers over time (particularly beyond 10 years) due to censoring limits the strengths of the data presented in the Kaplan–Meier plots.

CONCLUSIONS
The data from this study suggest that the mPERR status (responder vs non-responder) at 2 years post biopsy has prognostic value for the long-term renal outcomes of patients with LN and support the validity of mPERR as...
an endpoint when used in real-world studies. However, further observational studies in larger multicenter LN cohorts are required to confirm these findings.

Acknowledgements The authors thank Kerry Gairy for reviewing the data. Medical writing support was provided by Julia Eckhoff, PhD, and Liam Campbell, PhD, of Fishawack Indicia Ltd, UK, and was funded by GSK. The authors would like to thank the participating patients and their families, clinicians and study investigators.

Contributors DWG and MF acquired the data. SC, QF, YG, AM, and DAR designed the experiments and analysed the data. PJ analysed the data. All authors contributed to the development of the manuscript. PJ is the guarantor for this publication.

Funding This work was funded by the National Institute of Health (NIH grant R01-AR069572) and GSK (study number 213039).

Competing interests SCB and AM were employees of GSK at the time of the study. QF, YG, PJ and DAR are employees of GSK and hold shares in the company. DWG has nothing to disclose. MAP received research funding from GSK.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by Johns Hopkins University School of Medicine Institutional Review Board (Research Project Notification: NA_0003994).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Anonymised individual participant data and study documents can be requested for further research from ClinicalStudyDataRequest.com (www.clinicalstudyydatarequest.com).

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Patricia Julio http://orcid.org/0000-0001-6241-483X
Michelle A Petri http://orcid.org/0000-0003-1441-5373

REFERENCES

1. Anders H-J, Saxena R, Zhao M-H, et al. Lupus nephritis. Nat Rev Dis Primers 2020;6:7.
2. Hanly JG, O’Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology 2016;55:252–62.
3. Menez SP, El Essawy B, Atta MG. Lupus nephritis: current treatment paradigm and unmet needs. Rev Recent Clin Trials 2018;13:105–13.
4. Parikh SV, Almaani S, Brodsky S, et al. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis 2020;76:265–81.
5. Parodis I, Tamirou F, Houssiau FA. Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med 2020;7:e000389.
6. Bernatsky S, Boivin J-F, Josephy L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550–7.
7. Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol 2016;68:1432–41.
8. Yap DYH, Tang CSO, Ma MKM, et al. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 2012;27:3248–54.
9. Corapi KM, Dooley MA, Pendergraft WF. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther 2015;17:110.
10. van Vollenhoven R, Voiskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017;76:554–61.
11. Anders H-J, Rovin B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int 2016;90:493–501.
12. Davidson JE, Fu Q, Ji B, et al. Renal remission status and long-term renal survival in patients with lupus nephritis: a retrospective cohort analysis. J Rheumatol 2018;45:671–7.
13. Fangtham M, Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep 2013;15:16.
14. Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 2020;383:1117–28.
15. Dall’Era M, Cistulli PG, Smiley DE, et al. Predictors of long-term renal outcome in lupus nephritis: trials lessons from the Euro–Lupus Nephritis cohort. Arthritis Rheumatol 2015;67:1305–13.
16. Ugolini-Lopes MR, Seguro LPC, Castro MXF, et al. Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis? Lupus Sci Med 2017;4:e000213.
17. Wilson H, Turner-Stokes T, Griffith M, et al. Twenty years of lupus nephritis management - evaluation of a multi ethnic patient cohort to identify factors affecting outcome. Nephrol Dial Transplant 2018;33:92.
18. Tamirou F, Lauwerys BR, Dall’Era M, et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med 2015;2:e000123.
19. Kidney Disease Improving Global Outcomes (KDIGO), KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013;3:19–119.
20. Bose B, Silverman ED, Bargman JM. Ten common mistakes in the management of lupus nephritis. Am J Kidney Dis 2014;63:667–76.
21. GSK, Protocol CHS1121121 Amendment 07. Available: https://clinicaltrials.gov/ProvidedDocs/39/NCT01639339/Prot_000.pdf [Accessed 21 Jul 2020].
22. GSK. Reporting and analysis plan addendum for BEL114054. Available: https://clinicaltrials.gov/ProvidedDocs/39/NCT01639339/SAP_001.pdf [Accessed 21 Jul 2020].
23. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:40.
24. M, Orbi M, Araya-Gonzalez GS, et al. Validation and addition of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86.
25. Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521–30.
26. Fang H, Magder LS, Petri M. Distribution of urine protein/creatinine ratio by urinalysis protein dipstick score in systemic lupus erythematosus. Arthritis Rheum 2011;63.
27. Kasitano N, Fine DM, Haas M, et al. Estimating renal function in lupus nephritis: comparison of the Modification of Diet in Renal Disease and Cockcroft Gault equations. Lupus 2007;16:887–95.
28. Wilson H, Turner-Stokes T, Griffith M. Twenty years of lupus nephritis management - evaluation of a multi ethnic patient cohort to identify factors affecting outcome. Nephrol Dial Transplant 2018;33:92.
29. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70.
30. Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013;22:63–72.
31. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103–12.